492 related articles for article (PubMed ID: 29236593)
1. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG
J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593
[TBL] [Abstract][Full Text] [Related]
2. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
[TBL] [Abstract][Full Text] [Related]
3. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
4. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
6. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
[TBL] [Abstract][Full Text] [Related]
7. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.
Chandrasekar T; Gross L; Gomella LG; Hegarty SE; Leong JY; Giri VN
Eur Urol Oncol; 2020 Jun; 3(3):291-297. PubMed ID: 31278035
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
Loeb S; Giri VN
Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
[TBL] [Abstract][Full Text] [Related]
10. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
11. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract][Full Text] [Related]
12. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
13. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing for hereditary prostate cancer: Current status and limitations.
Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract][Full Text] [Related]
16. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
[TBL] [Abstract][Full Text] [Related]
17. Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Zeichner SB; Stanislaw C; Meisel JL
Oncology (Williston Park); 2016 Oct; 30(10):896-904. PubMed ID: 27753056
[TBL] [Abstract][Full Text] [Related]
18. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
Giri VN; Obeid E; Hegarty SE; Gross L; Bealin L; Hyatt C; Fang CY; Leader A
Prostate; 2018 Sep; 78(12):879-888. PubMed ID: 29655297
[TBL] [Abstract][Full Text] [Related]
19. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
